Clinical Information (ข้อมูลทางคลินิก):
GenomeHealth-Prestige is a premium genetic testing package offering complete genome coverage through Whole Genome Sequencing (WGS), decoding your entire genetic code to provide a comprehensive assessment of disease risks. It also includes pharmacogenomics (PGx) analysis for personalized and precise medication guidance, along with individualized DNA All Health testing to help you create a targeted and sustainable health management plan.
GenomeHealth-Prestige includes risk assessment for seven major disease groups: cancer, cardiovascular diseases, Malignant Hyperthermia (a severe reaction to anesthesia), Alzheimer’s disease, kidney disease, Myelodysplastic Syndrome and Acute Myeloid Leukemia (MDS/AML) and additional potential conditions (Additional Findings).
The package also offers pharmacogenomics (PGx) insights to support safe and effective drug selection tailored to your genetic profile, a comprehensive DNA All Health Report, and a specialized report for long-term brain health planning.
All genetic data is securely stored in accordance with international standards, allowing for future reanalysis as medical science continues to evolve.
The test includes genetic risk analysis for 7 disease groups, pharmacogenomic insights for medication adjustment, and a DNA All Health report for preventive health.
1.Cancer screening report: analyze 92 genes and report for 18 cancer types includes Breast Cancer, Ovarian Cance, Uterine Cancer, Colorectal Cancer, Cutaneous melanoma, Gastric Cancer, Pancreatic Cancer, Prostate Cancer, Renal cell cancer, Thyroid Cancer, Sarcoma, Leukemia, Brain cancer, Lung cancer, Endocrine cancer, Neuroendocrine, Retinoblastoma and Other related syndromes
2.Cardio screening report: analyze 98 genes and report for 6 cardio conditions includes Aortopathy, Arrhythmias, Cardiomyopathies, Genetic forms of high blood pressure and high cholesterol, Hereditary Hemorrhagic Telangiectasia and Thrombophilia
3.Malignant hyperthermia report: Analyzes 3 genes related to Malignant Hyperthermia condition.
4.Alzheimer’s disease risk report: Analyzes 3 genes and includes APOE genotyping, a key genetic marker strongly linked to Alzheimer’s susceptibility.
5.Kidney disease risk report: Analyzes 103 genes.
6.MDS/AML risk report: Analyzes 69 genes associated with myelodysplastic syndromes and acute myeloid leukemia.
7.Additional findings report: Analyzes 16 genes and reports on 11 additional conditions related to inborn errors of metabolism and miscellaneous phenotypes.
8.Pharmacogenomic report: Analyzes 19 genes to assess individual drug response, helping physicians select the most effective medications while minimizing potential side effects.
9.GenomeHealth SNP&Pick: Provides personalized recommendations on nutrition, exercise, and lifestyle adjustments tailored to your genetic profile, empowering you to live in harmony with your body.
Clinical Reference (เอกสารอ้างอิง):
1. Walsh N, Cooper A, D°Ckery A, O 'Byrne JJ. Variant reclassification and clinical implications. Journal of medical genetics. 2024 Mar 161(3):207-11.
2. Giau VV, Bagyinszky E, Youn YC, An SSA, Kim S. APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease. International Journal of Molecular Sciences. 2019 20(19):4757. https://doi.org/10.3390/ijms20194757
3. Knoers N, Antignac C, Bergmann C, et al. Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. Nephrol Dial Transplant. 202237(2):239-254. doi:10.1093/ndt/gfab218
4. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 200567(6):2089-2100. doi:10.1111/j.1523-1755.2005.00365.x
5. Stokman MF, Renkema KY, Giles RH, Schaefer F, Knoers NV, Van Eerde AM. The expanding phenotypic spectra of kidney diseases: insights from genetic studies. Nature Reviews Nephrology. 2016 Aug12(8):472-83.
6. Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. Int J Mol Sci. 2021 Dec 1022(24):13302. doi: 10.3390/ijms222413302.